NUVL Nuvalent, Inc.
USHealthcareAs of 2026-07-09 16:00
Why NUVL matters now
Nuvalent, Inc. (NUVL) is a US stock in Healthcare. The latest InvestLog snapshot shows $123.83 with +0.02% on the session and $9.11B in market capitalization; recent performance reads 1-month +22.21% and YTD +22.71%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-109.3M, and EPS of $-1.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.4%.
The latest indexable market news headline is "Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $124.00; recent insider activity includes Bogle Grant C. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.27
P/S
0.00
EV/EBITDA
-26.68
DCF Value
$3.22
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-42.8%
ROA
-33.8%
ROIC
-35.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-109.3M | $-1.39 |
| Q4 2025 | $0.00 | $-118.7M | $-1.58 |
| FY 2025 | $0.00 | $-425.4M | $-5.85 |
| Q3 2025 | $0.00 | $-122.4M | $-1.70 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$132.74
Target (Median)
$124.00
Target Range
$122.85 - $189.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.15
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.